Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Aug 23
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult…
17 Aug 23
This initiative underscores the growing importance of digital platforms in the medical education and the use of technology…
16 Aug 23
The partnership involves three separate multi-year collaborations, which allow Tentarix to receive a total of $66m in upfront…
16 Aug 23
Under the terms of the alliance, Parexel will serve as the preferred CRO provider for the Partex group…
16 Aug 23
The trial showed therapeutic equivalence in mean change of best corrected visual acuity (BCVA) from baseline to week…
16 Aug 23
MN-001 is an orally administered, small molecule compound with many mechanisms of action to treat chronic inflammatory and…
16 Aug 23
The partnership enables CytoMed to leverage CNK's PiggyBac technology, leveraging a non-viral gene editing approach, to permanently integrate…
16 Aug 23
The agreement offers Gritstone bio unrestricted access to Genevant's LNP technology, which will be applied alongside Gritstone bio's…
16 Aug 23
Under the agreement, AGC Biologics will leverage our monoclonal antibody development and manufacturing experience to perform process transfer,…
16 Aug 23
Precision Eligible to Receive up to $227m in Upfront Economics and Milestone Payments for Azer-Cel in Addition to…